Jaguar Health, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.62 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 842.63K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Details
| Name | Jaguar Health, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 47 |
| Founded | 2013 |
| Ceo | Lisa Conte |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US47010C8543 |
| Cusip | 47010C854 |
| Cik | 0001585608 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Lisa A. Conte | Founder, Chief Executive Officer, President and Director |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer and Chair of Scientific Advisory Board |
| Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer and General Counsel |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary |
| Carol R. Lizak M.B.A. | Chief Financial Officer and Treasurer |
| Peter Hodge | Senior Director of Investor Relations, Business Development and Special Events |
| David Sesin Ph.D. | Chief Manufacturing Officer |
| Ian H. Wendt M.B.A. | Chief Business Officer |
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International |
Contact
| Address | 200 Pine Street, Suite 400, San Francisco, California 94104, United States |
| Phone | 415 371 8300 |
| Website | https://jaguar.health |